Effects of varenicline on operant self-administration of alcohol and/or nicotine in a rat model of co-abuse

Behavioural Brain Research

Volumn 296, Issue , 2016, Pages 157-162

  Funk, D ^a   Lo, S ^a   Coen, K ^a   Le A D ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alcohol; Cues; Nicotine; Reinstatement; Self administration; Varenicline

Indexed keywords

VARENICLINE; ALCOHOL; NICOTINE; NICOTINIC AGENT;

ALCOHOL ABUSE; ALCOHOL CONSUMPTION; ALCOHOL SEEKING; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSOCIATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; MALE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; RAT; TOBACCO DEPENDENCE; TREATMENT RESPONSE; ADDICTION; ANIMAL; ANIMAL BEHAVIOR; DISEASE MODEL; DRUG DEPENDENCE; DRUG EFFECTS; DRUG INTERACTION; INSTRUMENTAL CONDITIONING; METABOLISM; WISTAR RAT;

ANIMALS; BEHAVIOR, ADDICTIVE; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; ETHANOL; MALE; NICOTINE; NICOTINIC AGONISTS; RATS; RATS, WISTAR; SUBSTANCE-RELATED DISORDERS; VARENICLINE;

EID: 84941978712     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.09.009     Document Type: Article

References (46)

1. Kinzeler N.R., Travers S.P. mu-Opioid modulation in the rostral solitary nucleus and reticular formation alters taste reactivity: evidence for a suppressive effect on consummatory behavior. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 301(3):R690-700.
2. Marchant N.J., Furlong T.M., McNally G.P. Medial dorsal hypothalamus mediates the inhibition of reward seeking after extinction. J. Neurosci. 2010, 30(42):14102-14115.
3. Istvan J., Matarazzo J.D. Tobacco, alcohol, and caffeine use: a review of their interrelationships. Psychol. Bull. 1984, 95(2):301-326.
4. Kandel D., et al. Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the U. S. population. Drug Alcohol Depend. 1997, 44(1):11-29.
5. Dani J.A., Harris R.A. Nicotine addiction and comorbidity with alcohol abuse and mental illness. Nat. Neurosci. 2005, 8(11):1465-1470.
6. Funk D., Marinelli P.W., Le A.D. Biological processes underlying co-use of alcohol and nicotine: neuronal mechanisms, cross-tolerance, and genetic factors. Alcohol Res. Health 2006, 29(3):186-192.
7. Tallarida R.J. Revisiting the isobole and related quantitative methods for assessing drug synergism. J. Pharmacol. Exp. Ther. 2012, 342(1):2-8.
8. Purohit V., Khalsa J., Serrano J. Mechanisms of alcohol-associated cancers: introduction and summary of the symposium. Alcohol 2005, 35(3):155-160.
9. King A., et al. Naltrexone decreases heavy drinking rates in smoking cessation treatment: an exploratory study. Alcohol. Clin. Exp. Res. 2009, 33(6):1044-1050.
10. King A., et al. Neural substrates of alcohol-induced smoking urge in heavy drinking nondaily smokers. Neuropsychopharmacology 2010, 35(3):692-701.
11. Fucito L.M., et al. Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. Biol. Psychiatry 2012, 72(10):832-838.
12. Le A.D., et al. Operant self-administration of alcohol and nicotine in a preclinical model of co-abuse. Psychopharmacology (Berl) 2014, 231(20):4019-4029.
13. Costello M.R., et al. Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats. Neuropsychopharmacology 2014, 39(8):1843-1851.
14. O'Connor E.C., et al. The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology (Berl) 2010, 208(3):365-376.
15. Wouda J.A., et al. Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. Psychopharmacology (Berl) 2011, 216(2):267-277.
16. Le Foll B., et al. Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used. Int. J. Neuropsychopharmacol. 2012, 15(9):1265-1274.
17. McKee S.A., et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol. Psychiatry 2009, 66(2):185-190.
18. Litten R.Z., et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. J. Addict. Med. 2013, 7(4):277-286.
19. Plebani J.G., et al. Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence. Drug Alcohol Depend. 2013, 133(2):754-758.
20. Hendrickson L.M., et al. Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption. J. Neurosci. 2010, 30(30):10169-10176.
21. Randall P.A., et al. The role of varenicline on alcohol-primed self-administration and seeking behavior in rats. Psychopharmacology (Berl) 2015.
22. Steensland P., et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(30):12518-12523.
23. Bito-Onon J.J., et al. Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats. Addict. Biol. 2011, 16(3):440-449.
24. Cippitelli A., et al. AT-1001: a high-affinity alpha3beta4 nAChR ligand with novel nicotine-suppressive pharmacology. Br. J. Pharmacol. 2015, 172(7):1834-1845.
25. Corrigall W.A., Coen K.M. Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 1989, 99(4):473-478.
26. Henderson-Redmond A., Czachowski C. Effects of systemic opioid receptor ligands on ethanol- and sucrose seeking and drinking in alcohol-preferring (P) and Long Evans rats. Psychopharmacology (Berl) 2014, 231(22):4309-4321.
27. Le A.D., et al. Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 1999, 21(3):435-444.
28. Hall B.J., et al. Bupropion-varenicline interactions and nicotine self-administration behavior in rats. Pharmacol. Biochem. Behav. 2015, 130:84-89.
29. Goeders N.E., et al. Effects of the combination of metyrapone and oxazepam on intravenous nicotine self-administration in rats. Psychopharmacology (Berl) 2012, 223(1):17-25.
30. Rollema H., et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007, 52(3):985-994.
31. George O., et al. Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration. Psychopharmacology (Berl) 2011, 213(4):715-722.
32. Rollema H., et al. Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition. Biochem. Pharmacol. 2009, 78(7):813-824.
33. Walker B.M., Zorrilla E.P., Koob G.F. Systemic kappa-opioid receptor antagonism by nor-binaltorphimine reduces dependence-induced excessive alcohol self-administration in rats. Addict. Biol. 2011, 16(1):116-119.
34. Walker B.M., et al. Alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol. Alcohol 2008, 42(2):91-97.
35. Chang Q., et al. Noribogaine reduces nicotine self-administration in rats. J. Psychopharmacol. 2015, 29(6):704-711.
36. Panlilio L.V., Hogarth L., Shoaib M. Concurrent access to nicotine and sucrose in rats. Psychopharmacology (Berl) 2014, 232(8):1451-1460.
37. Mitchell J.M., et al. Varenicline decreases alcohol consumption in heavy-drinking smokers. Psychopharmacology (Berl) 2014, 223(3):299-306.
38. Ginsburg B.C., Lamb R.J. Effects of varenicline on ethanol- and food-maintained responding in a concurrent access procedure. Alcohol. Clin. Exp. Res. 2013, 37(7):1228-1233.
39. Ginsburg B.C., Lamb R.J. Relative potency of varenicline or fluvoxamine to reduce responding for ethanol versus food depends on the presence or absence of concurrently earned food. Alcohol. Clin. Exp. Res. 2014, 38(3):860-870.
40. Le A.D., et al. Coadministration of intravenous nicotine and oral alcohol in rats. Psychopharmacology (Berl) 2010, 208(3):475-486.
41. Jimenez-Gomez C., Shahan T.A. Matching law analysis of rats' alcohol self-administration in a free-operant choice procedure. Behav. Pharmacol. 2008, 19(4):353-356.
42. McSweeney F.K., Swindell S., Weatherly J.N. Within-session changes in responding during concurrent schedules with different reinforcers in the components. J. Exp. Anal. Behav. 1996, 66(3):369-390.
43. Fredriksson I., et al. Evaluation of guanfacine as a potential medication for alcohol use disorder in long-term drinking rats: behavioral and electrophysiological findings. Neuropsychopharmacology 2015, 40:1130-1140.
44. Feduccia A.A., et al. Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens. Br. J. Pharmacol. 2014, 171(14):3420-3431.
45. Ericson M., et al. The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J. Pharmacol. Exp. Ther. 2009, 329(1):225-230.
46. Schassburger R.L., et al. Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline. Psychopharmacology (Berl) 2014, 232(5):975-983.